Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.
Vannucchi AM, Sordi B, Morettini A, Nozzoli C, Poggesi L, Pieralli F, Bartoloni A, Atanasio A, Miselli F, Paoli C, Loscocco GG, Fanelli A, Para O, Berni A, Tassinari I, Zammarchi L, Maggi L, Mazzoni A, Scotti V, Falchetti G, Malandrino D, Luise F, Millotti G, Bencini S, Capone M, Piccinni MP, Annunziato F, Guglielmelli P; RUXO-COVID Study Group. Vannucchi AM, et al. Among authors: atanasio a. Leukemia. 2021 Apr;35(4):1121-1133. doi: 10.1038/s41375-020-01018-y. Epub 2020 Aug 19. Leukemia. 2021. PMID: 32814839 Free PMC article. Clinical Trial.
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis.
Guglielmelli P, Maccari C, Sordi B, Balliu M, Atanasio A, Mannarelli C, Capecchi G, Sestini I, Coltro G, Loscocco GG, Rotunno G, Angori E, Borri FC, Tefferi A, Vannucchi AM. Guglielmelli P, et al. Among authors: atanasio a. Blood Cancer J. 2023 Jan 30;13(1):21. doi: 10.1038/s41408-023-00786-x. Blood Cancer J. 2023. PMID: 36710362 Free PMC article. No abstract available.
Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy.
Atanasio A, Vanni A, Maggi L, Pilerci S, Mazzoni A, Capone M, Crupi F, Cicogna P, Boldrini V, Tekle S, Colao MG, Borella M, Paoli C, Rossolini GM, Vannucchi AM, Annunziato F, Guglielmelli P. Atanasio A, et al. Leuk Res. 2023 Aug;131:107330. doi: 10.1016/j.leukres.2023.107330. Epub 2023 May 29. Leuk Res. 2023. PMID: 37269750 Free PMC article. No abstract available.
CALR mutation burden in essential thrombocythemia and disease outcome.
Guglielmelli P, Szuber N, Gangat N, Capecchi G, Maccari C, Harnois M, Karrar O, Abdelmagid M, Balliu M, Nacca E, Atanasio A, Sestini I, Désilets A, Loscocco GG, Rotunno G, Busque L, Tefferi A, Vannucchi AM. Guglielmelli P, et al. Among authors: atanasio a. Blood. 2024 Mar 28;143(13):1310-1314. doi: 10.1182/blood.2023023428. Blood. 2024. PMID: 38252902
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib.
Coltro G, Capecchi G, Maffioli M, Mannelli F, Mora B, Atanasio A, Iurlo A, Maccari C, Farina M, Nacca E, Caramella M, Signori L, Borella M, Bertù L, Esposito M, Guglielmelli P, Passamonti F, Vannucchi AM. Coltro G, et al. Among authors: atanasio a. Haematologica. 2024 May 30. doi: 10.3324/haematol.2024.285098. Online ahead of print. Haematologica. 2024. PMID: 38813708 Free article.
Production of large, defined genome modifications in rats by targeting rat embryonic stem cells.
Lee J, Wang J, Ally R, Trzaska S, Hickey J, Mujica A, Miloscio L, Mastaitis J, Morse B, Smith J, Atanasio A, Chiao E, Chen H, Latuszek A, Hu Y, Valenzuela D, Romano C, Zambrowicz B, Auerbach W. Lee J, et al. Among authors: atanasio a. Stem Cell Reports. 2023 Jan 10;18(1):394-409. doi: 10.1016/j.stemcr.2022.11.012. Epub 2022 Dec 15. Stem Cell Reports. 2023. PMID: 36525967 Free PMC article.
18 results